A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic

0	
7 8 9 10 11 12 13 14 15	Maria Alimova ¹ , Eriene-Heidi Sidhom ^{1,2} , Abhigyan Satyam ³ , Moran Dvela-Levitt ^{1,2} , Michelle Melanson ¹ , Brian T. Chamberlain ¹ , Seth L. Alper ^{1,3} , Jean Santos ¹ , Juan Gutierrez ¹ , Ayshwarya Subramanian ¹ , Elizabeth Grinkevich ¹ , Estefania Reyes Bricio ¹ , Choah Kim ^{1,2} , Abbe Clark ¹ , Andrew Watts ^{1,2} , Rebecca Thompson ¹ , Jamie Marshall ¹ , Juan Lorenzo Pablo ¹ , Juliana Coraor ^{1,2} , Julie Roignot ¹ , Katherine A. Vernon ^{1,2} , Keith Keller ^{1,2} , Alissa Campbell ^{1,2} , Maheswarareddy Emani ¹ , Matthew Racette ¹ , Silvana Bazua-Valenti ^{1,2} , Valeria Padovano ¹ , Astrid Weins ² , Stepher P. McAdoo ⁴ , Frederick W.K. Tam ⁴ , Lucienne Ronco ¹ , Florence Wagner ¹ , George C. Tsokos ³ , Jillian L. Shaw ¹ , Anna Greka ^{1,2}
16	1. The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
17	2. Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts,
18	USA.
19	3. Beth Israel Deaconess Medical Center and Harvard Medical School, Boston,
20	Massachusetts, USA.
21	4. Department of Immunology and Inflammation, Imperial College, Hammersmith Hospita
22	London, UK
23 24 25 26	Author List Footnotes Correspondence to: Anna Greka, MD, PhD, <u>agreka@bwh.harvard.edu</u>
27 28 29 30 31	

32

33 Summary

34

35 Drug repurposing is the only method capable of delivering treatments on the shortened time-36 scale required for patients afflicted with lung disease arising from SARS-CoV-2 infection. 37 Mucin-1 (MUC1), a membrane-bound molecule expressed on the apical surfaces of most 38 mucosal epithelial cells, is a biochemical marker whose elevated levels predict the development 39 of acute lung injury (ALI) and respiratory distress syndrome (ARDS), and correlate with poor 40 clinical outcomes. In response to the pandemic spread of SARS-CoV-2, we took advantage of a 41 high content screen of 3,713 compounds at different stages of clinical development to identify 42 FDA-approved compounds that reduce MUC1 protein abundance. Our screen identified 43 Fostamatinib (R788), an inhibitor of spleen tyrosine kinase (SYK) approved for the treatment of 44 chronic immune thrombocytopenia, as a repurposing candidate for the treatment of ALI. In vivo, 45 Fostamatinib reduced MUC1 abundance in lung epithelial cells in a mouse model of ALI. In 46 vitro, SYK inhibition by Fostamatinib promoted MUC1 removal from the cell surface. Our work 47 reveals Fostamatinib as a repurposing drug candidate for ALI and provides the rationale for 48 rapidly standing up clinical trials to test Fostamatinib efficacy in patients with COVID-19 lung 49 injury.

50

51 52

53 Keywords

54 COVID-19, SARS-CoV-2, MUC1, acute respiratory distress syndrome (ARDS), acute lung
 55 injury (ALI), Fostamatinib, drug repurposing

56

57 58

59 Introduction

60

61 Drug repurposing is a strategy to identify novel uses for approved or investigational 62 drugs outside the scope of their originally designated purposes. This approach offers several advantages over *de novo* drug development (Ashburn and Thor, 2004; Pushpakom et al., 2019). 63 64 First and foremost, the risk of toxicity is much lower as repurposed approved drugs have been 65 proven safe for human use in the original indication. Second, and of critical importance for 66 addressing the global public health crisis attributed to SARS-CoV-2, is that drug repurposing 67 offers the only method for delivering treatments on the shortened time-scale required to treat 68 COVID-19 patients. Current management of COVID-19 is largely supportive and with severely 69 limited therapeutic options. Once infection with SARS-CoV-2 is established, a subset of patients 70 experience severe complications such as acute respiratory distress syndrome (ARDS), an 71 extreme form of acute lung injury characterized by disruption to the alveolar epithelium (Ruan et 72 al., 2020; Zhou et al., 2020). ARDS is a life-threatening condition with mortality rates as high as 73 40% (Acute Respiratory Distress Syndrome et al., 2000; Determann et al., 2010; Rubenfeld et 74 al., 2005). COVID-19-associated ARDS is often fatal, especially in the presence of several pre-75 existing conditions. The currently limited therapeutic interventions available for COVID-19 76 (Cao et al., 2020; Grein, 2020) have contributed to an estimated 400,000 deaths worldwide at the 77 time of writing (Dong et al., 2020). Identification of drugs with efficacy in treating ALI in 78 severely affected COVID-19 patients remains an urgent need.

79

80 ARDS patients exhibit high serum levels of mucin-1/MUC1 (KL-6) (Nakashima et al., 81 2008). MUC1 is a transmembrane protein expressed on the apical membrane of most mucosal 82 epithelial cells and plays a critical role in lining the airway lumen (Kato et al., 2017). Mucins are 83 glycoproteins that impart specific properties to mucus. In response to specific stimuli, goblet 84 cells can rapidly secrete mucus by exocytosis to form a mucus layer that lines the airways. In 85 healthy individuals, mucus along the lumen serves as a major protective barrier against inhaled 86 pathogens, toxins, and other foreign particles. However, excessive mucus in the airways has been 87 linked to increased frequency and duration of infections, decreased lung function, and increased 88 mortality from respiratory diseases (Vestbo, 2002). Abnormalities in mucus production 89 contribute to severe pulmonary complications and death from respiratory failure in patients with 90 diseases such as cystic fibrosis, chronic obstructive pulmonary disease (COPD), and acute lung 91 injury due to viral pathogens, such as SARS-CoV2. Elevated serum KL-6/MUC1 levels are an 92 early prognostic marker of the therapeutic effect of high-dose corticosteroids in patients with 93 rapidly progressing idiopathic pulmonary fibrosis (Yokoyama et al., 1998). Serum KL-6/MUC1 94 levels are also elevated in patients with interstitial pneumonitis (Ishikawa et al., 2012; Kohno, 95 1999). Moreover, transgenic mice expressing human MUC1 and subjected to LPS-induced ALI 96 exhibit elevated KL-6 both in alveolar pneumocytes and in serum (Sakai et al., 2013).

97

98 Prompted by the connection between elevated MUC1 and ALI, we investigated the 99 possibility of identifying MUC1-reducing drugs for rapid repurposing. We had originally 100 screened the Broad Repurposing Library (comprised of 3,713 compounds at different stages of 101 pre-clinical and clinical development (Corsello et al., 2017)) to identify compounds capable of 102 reducing a mutant MUC1 neo-protein (MUC1-fs) causing autosomal dominant tubulo-interstitial 103 kidney disease-mucin1 (ADTKD-MUC1 or MUC1 kidney disease, MKD) (Dvela-Levitt et al., 104 2019). In this context wildtype MUC1 (MUC1-wt) served as a control, as we sought compounds 105 that specifically reduced the mutant, but not the wildtype form of MUC1. As the number of 106 COVID-19 cases increased globally, we turned our attention to identifying MUC1-reducing 107 compounds and mined this dataset to identify approved drugs that reduce expression of MUC1-108 wt. We searched for MUC1-reducing compounds based on the following criteria: 1) a drug that 109 reduces MUC1-wt protein in a dose-dependent manner; 2) a drug with a favorable toxicity 110 profile; 3) a drug that reduces MUC1-wt by non-transcriptional mechanisms (Dvela-Levitt et al., 111 2019), unlike transcriptional suppressors such as vitamin D agonists that have proven ineffective 112 in the clinic (Castro et al., 2014); and 4) a drug that is US Food and Drug Administration (FDA)-113 approved. Based on these criteria, our screen identified R406, the active metabolite of 114 Fostamatinib (R788, an oral prodrug rapidly converted to R406), as a repurposing candidate for 115 the treatment of ALI.

116

117

118 **Results**

119

The FDA approved SYK inhibitor R406 depletes MUC1 from epithelial cells without affecting cell viability

122

123 To investigate the expression pattern of MUC1 in human tissue, we took advantage of the 124 openly available Human Protein Atlas (HPA)(<u>www.proteinatlas.org</u>) (Uhlen et al., 2015). Immunoperoxidase staining of human lung showed MUC1 expression in alveolar epithelium.
This finding confirmed multiple reports of MUC1 expression in normal and diseased human lung
(Figure 1A) (Ishizaka et al., 2004; Ohtsuki et al., 2007). These data were corroborated by the
expression of MUC1 mRNA in human lung reported by the HPA, GTEx and FANTOM5
databases (Figure 1B) and by the Human Lung Atlas project (Muus, 2020)

129 130

131 We screened 3,713 compounds of the Repurposing Library for their ability to reduce 132 MUC1 protein levels (Figure 2A). The screen employed high-content immunofluorescence (IF) 133 imaging of an immortalized kidney tubular epithelial cell line (P cells) that express endogenous 134 MUC1 on the plasma membrane, to simultaneously assess MUC1 protein abundance and cell 135 number as an index of cell toxicity (Dvela-Levitt et al., 2019). The bromodomain inhibitor JQ1 136 served as positive control, as preliminary experiments demonstrated complete transcriptional 137 suppression of MUC1 by JQ1. Each compound in the Repurposing Library was tested in a 5 138 concentration, 10-fold dilution series with a top concentration of 35 μ M in the initial screen. 139 Positive hits from the 5-dose screen were defined by two criteria: lack of cellular toxicity (less 140 than 20% reduction in cell number compared to the DMSO control); and reduction of MUC1 141 abundance by >30% (normalized to DMSO and JQ1 controls) at 2 or more consecutive non-toxic 142 concentrations of test compound. The compounds that met these criteria included two major 143 groups, bromodomain inhibitors (blue) and vitamin D receptor agonists (orange, Figure 2B). Our 144 screen also identified drugs that increased MUC1 levels (Figure 2B), including glucocorticoid 145 receptor agonists. Most compounds that increased MUC1, such as epidermal growth factor 146 receptor (EGFR) inhibitors (green), also reduced cell number, indicating an association between 147 cell toxicity and increased MUC1 levels (Figure 2B).

148

149 Two hundred and three compounds were re-tested at 10 concentrations to generate more 150 complete dose response curves for each compound. In this screen, any compound that reduced 151 MUC1 by >30% at 2 or more consecutive concentrations without evidence of toxicity (cell 152 numbers within 20% of the DMSO control) was considered a positive hit. Thirteen hits from this 153 screen were analyzed further in secondary profiling assays, including quantitative PCR (qPCR) 154 and cell viability screens. MUC1 qPCR (Figure 2C) showed that for most compounds, reduction 155 of MUC1 protein abundance (MUC1 IF) was highly correlated with parallel reductions in 156 mRNA abundance (MUC1 qPCR). Of interest, 4 compounds reduced MUC1 protein without 157 affecting MUC1 mRNA. These included the SYK inhibitor R406 (red, Figure 2C); the RAF 158 inhibitor LGX818 (violet, Figure 2C); the mannosidase inhibitor Kifunensine (green, Figure 2C), 159 and the IKK inhibitor TPCA-1 (turquoise, Figure 2C). None of these four compounds exhibited 160 detectable toxicity (cell death or apoptosis) at any of the 10 tested concentrations. Importantly, 161 only the SYK inhibitor R406 is FDA-approved (Figure 2A and D). No additional compounds 162 with known activity against SYK met our screening criteria. R406 decreased MUC1 protein 163 abundance in cells with an EC50 of approximately 200 nM. The lack of effect on MUC1 mRNA 164 levels (as shown by qPCR) indicated that MUC1 protein reduction was not achieved via 165 transcriptional repression (representative images of cells treated with R406 at a range of 166 concentrations; Figure 2E). The parent molecule of R406, Fostamatinib (R788), showed no 167 activity in the initial 5-concnetration screen. 168

- 169 **R406** preferentially depletes MUC1 from the plasma membrane
- 170

171 Image analysis from the high content screen revealed that, while MUC1 was 172 preferentially localized to the plasma membrane in DMSO-treated control cells, treatment with 173 200 nM of R406 reduced MUC1 from the plasma membrane and redistributed a fraction of the 174 protein to the intracellular compartment with a perinuclear distribution pattern (Figure 3A). We 175 quantified this relocalization using a STAR morphology "Profile" Module (Star Methods) that 176 allowed selective measurement of MUC1 signal distribution in cellular sub-compartments. 177 Figure 3B shows an analysis sequence for the sub-compartment corresponding to the cell region 178 closest to the plasma membrane. Within each cell, the nucleus border was identified based on 179 Hoechst staining (blue, second panel, Figure 3B) and the plasma membrane (orange, second 180 panel, Figure 3B) was identified based on the MUC1 signal. The calculated STAR morphology 181 "Membrane Profile" image was generated as illustrated in Figure 3B, panel 3 (STAR Methods). 182 The calculated STAR Membrane Profile values for MUC1 in each well were compared with total 183 cell MUC1 intensity (Figure 3C). As shown by a local regression, while most compounds that 184 decreased MUC1 did not affect MUC1 membrane localization, R406 produced preferential 185 depletion of MUC1 from the plasma membrane region at all active concentrations.

186

187 *In vivo*, R406 reduces lung epithelial MUC1 in mice with ALI

188

189 SYK inhibition has previously been shown to suppress both local and remote lung injury 190 (Pamuk, et al., 2010). R788 (fostamatinib disodium) is a methylene phosphate prodrug of R406 191 suitable for oral administration (McAdoo and Tam, 2011). To investigate whether administration 192 of R788 might ameliorate ischemia-reperfusion (I/R)-induced remote lung injury by reducing 193 MUC1 levels from the plasma membrane in the lung epithelium, C57BL/6J mice were fed a 194 chow diet containing 3 grams/kilogram of R788 for 10 days. Immunohistochemical images 195 obtained from formalin-fixed paraffin sections of lung tissues stained with MUC1, Phalloidin, 196 and DAPI demonstrated that I/R-mediated ALI induced increased levels of MUC1 in lung 197 epithelium, consistent with previous reports that excess MUC1 is injurious (Sakai et al., 2013). 198 Importantly, MUC1 was significantly reduced by treatment with R788 (Figure 4A). Quantitative 199 image analysis confirmed the in vivo efficacy of R788 in reducing MUC1 in injured lung

200 epithelium (Figure 4B and C).

201

202 Discussion

203

204 Our high-content screen identified R406, the active metabolite of Fostamatinib, as an 205 FDA-approved candidate repurposing compound for the reduction of MUC1 protein levels in 206 lung epithelium in the setting of ALI. R406 is a potent inhibitor of spleen tyrosine kinase (SYK), 207 a cytosolic protein tyrosine kinase required for the expression of several proinflammatory 208 cytokines (Yi et al., 2014). SYK is expressed in most leukocyte populations with roles in 209 mediating signaling via classical immunoreceptors such as B-cell receptors and Fc receptors 210 (Mocsai et al., 2010). SYK plays diverse roles in cellular adhesion, innate immune recognition, 211 and platelet activation, and its central role in immune cell responses has made it a compelling 212 target for the development of therapeutic agents. Over 70 patent filings describe small molecule 213 inhibitors of SYK developed for treatment of diseases ranging from arthritis to asthma (Geahlen, 214 2014).

216 Fostamatinib is an effective treatment in experimental animal models of severe 217 inflammatory diseases, including immune glomerulonephritis (McAdoo et al., 2014; Smith et al., 218 2010) and vasculitis (McAdoo et al., 2020). Phase II clinical trial results are expected assessing 219 the effect of SYK inhibition in proliferative IgA nephropathy, an inflammatory kidney disease 220 (NCT02112838). Fostamatinib was approved in April 2018 by the US Food and Drug 221 Administration (FDA) for the treatment of chronic immune thrombocytopenia (ITP), an 222 autoimmune disease that results in low levels of circulating platelets (Argade et al., 2015; 223 Hilgendorf et al., 2011; Newland et al., 2018; Singh et al., 2012). Fostamatinib has also been 224 extensively studied and found to be safe in more than 3000 patients with rheumatoid arthritis 225 (Kunwar et al., 2016). In a Phase III clinical trial (Bussel et al., 2018), Fostamatinib was well 226 tolerated at an oral dose of 100 mg twice daily. Mild or moderate adverse effects included 227 diarrhea, hypertension, nausea, and an increase in alanine aminotransferase (ALT). These 228 resolved spontaneously or with medical management, including antihypertensive or antimotility 229 agents. This well-characterized clinical safety profile makes Fostamatinib an ideal candidate for 230 rapid repurposing (Weinblatt et al., 2010).

231

232 Our finding that R406 preferentially depletes MUC1 abundance in or near the plasma 233 membrane is consistent with a previously described mechanism by which SYK inhibition results 234 in dephosphorylation of integral membrane proteins followed by their endocytic removal from 235 the plasma membrane. For example, SYK signaling modulates CFTR abundance in human 236 airway epithelial cell plasma membrane (Mendes et al., 2011). Interestingly, SYK in mucin-237 producing human NCI-H292 cells and in primary human nasal epithelial cells also regulates 238 MUC5AC, a gel-like mucin that promotes lung epithelial injury (Na et al., 2016). Finally, in 239 further support of the notion that MUC1 reduction is beneficial to injured lung epithelium, Muc1 240 knockout in rat airway epithelial cells and MUC1 reduction in human lung epithelium resulted in 241 diminished mucin hypersecretion and protection from lung injury (Kato et al., 2020).

242

243 Severe COVID-19 symptoms include viral-induced pneumonitis accompanied by 244 prolonged, systemic cytokine release (Moore and June, 2020; Zhang et al., 2020) in which levels 245 of interleukin-6 (IL-6) levels and other cytokines and acute phase reactants correlate with 246 respiratory failure. Macrophage-derived IL-6 upregulates MUC1 in the human colon cancer HT-247 29 cell line (Li et al., 2009), suggesting a similar IL6-mediated upregulation of MUC1 may occur 248 in SARS-CoV-2 infected lungs. A recent comparison of 15 hospitalized COVID-19 patients, 9 249 of whom were critically ill, to 28 critically ill patients with ARDS or sepsis found no statistically 250 significant difference in circulating levels of IL-1b, IL-1RA, IL-6, IL-8 and TNF-alpha among 251 these conditions (Wilson, 2020). These results indicate that COVID19-related ARDS is 252 associated with inflammatory cytokine levels no higher than in ARDS due to other critical 253 illnesses (Wilson, 2020). Another recent study analyzing serum concentrations of KL-6/MUC1 254 levels in hospitalized COVID19 patients suggested KL-6/MUC1 as a good prognostic biomarker 255 of disease severity in COVID-19 patients (d'Alessandro et al., 2020). Given the roles of excess 256 KL6/MUC1 in ALI and ARDS, we propose that Fostamatinib may confer benefit in patients with 257 COVID-19 lung injury. In conclusion, our *in vitro* and *in vivo* data support the efficacy of 258 Fostamatinib for the treatment of ALI. Here we provide a rationale for imminently designing and 259 executing clinical trials to test whether repurposing this FDA-approved drug might confer 260 clinical benefit for COVID-19 patients in the clinic.

- 262
- 263
- 264

265 Acknowledgments

- 266 We gratefully acknowledge stimulating discussions with Broad colleagues Deborah Hung,
- Ramnik Xavier, Jay Rajagopal and Aviv Regev. We thank Terry Woo (BWH Pathology) and
 Stephen Straub (Perkin Elmer) for excellent technical support and expertise. SYK inhibitor R788
- 269 was provided as a gift to GCT by Rigel Pharmaceuticals (South San Francisco, CA).
- 270
- 271 This work was supported by PHS NIH R01AI148161 (GCT) and by the Slim Initiative for
- 272 Genomic Medicine in the Americas (SIGMA), a collaboration of the Broad Institute with the
- 273 Carlos Slim Foundation. FWKT is supported by the Ken and Mary Minton Chair of Renal274 Medicine.
- 274
- 275
- 270
- 277 278

279 Author Contributions

- 280 MA, ASat, MDL, MM, JS, JG performed experiments; MA, EHS, ASat, MDL, BC, ASub
- 281 performed data analysis and provided data visualization; SMcA, FT, GCT provided tissue and
- expertise in rodent models of lung disease; MA, EHS, MDL, BC, JS and AG wrote the
- 283 manuscript; all authors participated in discussions on the scientific rationale for this study, read
- and approved the manuscript; AG supervised the project.
- 285

286 **Declaration of Interests**

- 287 The authors declare no competing interests.
- 288 FWKT has received research project grants from Rigel Pharmaceuticals, and has consultancy
- agreements with Rigel Pharmaceuticals, and is the Chief Investigator of an international clinical
- trial of a SYK inhibitor in IgA nephropathy (ClinicalTrials.gov NCT02112838), funded by Rigel
- 291 Pharmaceuticals.
- 292
- 293
- 294

295 Figure Legends

296 297

Figure 1. High relative expression of MUC1 in human lung.

- A. Immunoperoxidase staining of three human lung samples demonstrates MUC1 protein
 abundance in lung tissue.
- 302 B. mRNA expression data from three datasets (HPA, GTEx, and FANTOM5, heatmaps)
- 303 combined into a CONSENSUS normalized transcript expression level (bar plot) show
- 304 enhanced expression of MUC1 mRNA in human lung. NX, normalized
- 305 expression; pTPM, protein-coding transcripts per million.
- 306

307 Figure 2. High Content Screening reveals significant and dose-dependent reduction in 308 MUC1 by the FDA-approved SYK inhibitor R406

- 309 A. Screening pipeline.
- 310 B. Primary screen revealed four major groups of compounds which affected MUC1
- 311 levels. MUC1 immunofluorescence (IF) signal intensity per cell (normalized to positive
- 312 control JQ1 minus DMSO-treated controls) plotted vs. DMSO-normalized cell number.
- 313 Horizontal and vertical dashed lines delineate mean DMSO values +/- 3*SD for both 314 MUC1 intensity and cell number. Lavender-shaded area demarcates candidate MUC1
- 315 suppressors.
- 316 C. qPCR and cell viability profiling screens identified four compounds that reduced 317 MUC1 protein abundance without changing MUC1 mRNA level, and in the absence of 318 cytotoxicity. Left: MUC1 signal intensity per cell plotted vs. MUC1 mRNA level (qPCR 319 assay). Both parameters are normalized to JQ1 minus DMSO-treated controls. Right: JQ1
- 320 minus DMSO-normalized MUC1 signal intensity per cell plotted vs. DMSO-normalized 321 cell viability (a number of viable cells after 6 days exposure to the test compounds).
- 322 Horizontal dashed lines delineate SD for DMSO treated control wells for both cell 323 viability and MUC1 qPCR. Green-shaded areas demarcate candidate hits.
- 324 D. R406 concentration response curves for MUC1 protein abundance (black), MUC1 325
 - mRNA abundance (light gray), and cell viability (dark gray).
- 326 E. MUC1 IF in kidney epithelial cells treated for 48 hours in the absence (DMSO) and 327 presence of R406 at the indicated concentrations. 328

329 Figure 3. R406 preferentially depletes MUC1 from the plasma membrane.

- 330 A. R406 (at EC50 concentration) substantially reduced MUC1 abundance in or near the 331 plasma membrane, with a portion of MUC1 retained in cytosolic and perinuclear cell 332 compartments.
- 333 B. Image analysis for cell compartmentation using STAR morphology "Membrane -334 Profile" calculation (see Star Methods). Image 1: cells with MUC1 preferentially
- 335 localized at plasma membrane; Image 2: Harmony software identification of nucleus 336 (blue) and plasma membrane (gold) in each cell; Image 3: STAR morphology
- 337 "Membrane Profile" for the MUC1 predominant localization within membrane 338 compartment
- 339 C. STAR morphology" Membrane Profile" analysis of 203 compounds screened at 10 340 doses. R406 at most active concentrations reduced plasma membrane MUC1 abundance 341 to a greater degree than most other compounds, as shown by deviation from the local 342 regression. MUC1 IF signal intensity per cell (normalized to JO1 minus DMSO-treated 343 controls) plotted vs. DMSO-normalized MUC1 predominance in plasma membrane
- 344 region as calculated using the STAR morphology "Membrane Profile" module. 345 Horizontal and vertical dashed lines delineate mean DMSO values +/- 2*SD for both
- 346 plotted parameters. Local regression was calculated by locally estimated scatterplot
- 347 smoothing (loess) method +/- 95% confidence interval (gray-shaded).
- 348 349

350 Figure 4. In vivo, R788 reduces excess MUC1 from lung epithelia of mice with ALI

- A. Immunofluorescence images from lung tissue sections stained with MUC1 (green),
 Phalloidin (yellow), and DAPI (grey) demonstrate that ischemia-reperfusion (I/R) induced remote ALI resulted in increased MUC1 in lung epithelium. Treatment with
 Fostamatinib over the course of 10 days suppressed MUC1 levels in mouse lung
 epithelium.
- B. Single cell tissue analysis, based on immunofluorescence of MUC1 and phalloidin (panel
 1). In each image (panel 1) nuclei were identified based on DAPI staining (rainbow
 colors represent different cell nuclei in panel 2). The cell bodies were identified based on
 phalloidin staining surrounding each nucleus (orange cell borders, panel 3). Lastly,
 MUC1 IF intensity (green on panel 3) and Phalloidin intensities were calculated within
- 362 each cell body.
- 363C. Bar graph ratio of MUC1/Phalloidin intensities in all cells of tissue sections from sham-364treated mice and mice subjected to I/R-induced ALI, treated either with or without365Fostamatinib. Average MUC1 intensity values per cell were normalized to the average366phalloidin levels. Mean \pm SD (n = 3 mice/condition/dose). ns, *p < 0.05 **p < 0.01 ***p <</td>3670.001.

369 STAR Methods

370

368

371 Broad Repurposing Library

372

Quality control of The Broad Repurposing Library is performed at the time of plating by LCMS
 analysis using a Waters Acquity LC System with UV PDA detector and single quad (SQ) mass
 spectrometer R406 was confirmed present (MS (ESI/SQ) m/z: [M + H]+ Calculated for

376 C22H23FN6O5+H: 471.2; Found: 470.9) in > 97% purity (PDA integration).

377

378 Human Protein Atlas

379

MUC1 immunoperoxidase images were obtained from the Human Protein Atlas with the original source available at the following link: (<u>https://www.proteinatlas.org/ENSG00000185499-</u>

- 382 <u>MUC1/tissue/lung</u>). mRNA expression data (<u>https://www.proteinatlas.org/ENSG00000185499-</u>
- 383 <u>MUC1/tissue</u>) were downloaded from the Human Protein Atlas:
- 384 (<u>http://www.proteinatlas.org/ENSG00000185499.xml</u>) (Uhlen et al., 2015). All graphs were
 385 visualized using ggplot2.
- 386

387 Experimental Models

388389 Cell Lines

- Human P kidney epithelial cells (female) were previously generated from a patient with MUC1
- kidney disease (Dvela-Levitt et al., 2019). The cells were maintained at 37°C with 5% CO2 in
- 392 RenaLife Renal Basal Medium supplemented with RenaLife LifeFactors® (Lifeline Cell
- 393 Technology), with the exclusion of Gentamycin and Amphotericin B. For all experiments, P cells
- 394 were maintained below passage 12. The cells were generated with informed consent under
- 395 WFUHS IRB00014033.
- 396
- 397

398 Fluorescence image acquisition and analysis

399

400 All fluorescence imaging performed in this study was done using the Opera Phenix High-

401 Content Screening System (PerkinElmer). For fluorescence imaging of cells (live cell or fixed

402 cell imaging), CellCarrier 384-well Ultra microplates (Perkin Elmer) were used, and a minimum

403 of nine fields was acquired per well using 20x water immersion objectives in a confocal mode.

404

405 Image analysis for all imaging experiments was performed using the Harmony software

406 (PerkinElmer). Cell nuclei were first identified using Hoechst staining, and cell number was

407 calculated. Cytoplasmic regions were then detected around each nucleus based on MUC1

408 channel. The cells from the edge of the field were eliminated from the analysis. For the

409 quantification of MUC1 abundance, the total signal intensity value was calculated in the cell

- 410 cytoplasm and the average signal per cell was calculated for each well.
- 411

412 For live cell image analysis, caspase 3/7 activation and/or DRAQ7 signal were used to detect

413 cells going through apoptosis and/or cell death, respectively. Single cells were first identified

414 using the digital phase contrast channel and cell number was calculated. Fluorescence intensities

415 were then measured and the threshold for caspase 3/7 and DRAQ7 positive signal was

416 determined. As an output, the number of live (neither caspase3/7 nor DRAQ7 signal detected)

417 cells was calculated in each well at a particular time point.

418

419 For the MUC1 membrane prevalence, the images acquired during 10-dose screening were

420 analyzed using the Harmony software STAR morphology feature, which calculates the signal

421 distribution across different cell compartments. The inner side of plasma membrane compartment

422 was analyzed by generating a "Membrane Profile Image" (profile 1/5 in Harmony software) (fig

423 3B). This function measures the closest distance of a given pixel to a cell border within a width

424 of 4 pixels to preferentially weigh and quantify signal intensity (MUC1) closest to the plasma

425 membrane signal.

426 For in vivo lung imaging, 20x water immersion objective was used, with 5% overlap for entire

427 lung sections. Tissue Image Region for every tissue section was identified based on Gaussian

428 Smoothed filtered global DAPI channel. Every Tissue Image Region was resized to exclude the

429 very peripheral area of the sections. Sliding parabola filtered DAPI channel within the resized

430 tissue area was used to find nuclei; and Phalloidin was used to identify a cytoplasm (see fig 4B).

431 Mean intensity of MUC1 and Phalloidin was calculated in each cell, and averaged per cell for the

432 entire tissue sample. The average MUC1 signal was then normalized to Phalloidin signal to take

433 in account variability in slide staining conditions.

434 High Content Screening

435 The automated high content screening system consisted of robotic arms; plate stackers; a

436 HighRes Pin Tool; Liconic incubators; Biotek plate washers; dedicated Thermo Fisher Combi

437 Multidrop dispensers for each assay reagent; and PerkinElmer High Content Imaging Instrument

438 Opera Phenix, all choreographed by Cellario software. Cell fixation and immunostaining were all

439 performed in a custom-designed light-protected hood (HighRes Biosolutions). Data analysis and

440 representation was performed using Genedata Screener (Genedata AG) and Spotfire (TIBCO).

441 For the immunofluorescence screen, P cells were seeded 24 h prior to compound treatment at a 442 density of 12,000 cells/well in 384 well CellCarrier Ultra plates (Perkin Elmer), pre-coated with 443 0.25 mg/mL Synthemax II SC Substrate (Corning). Compounds of the repurposing library set 444 (Corsello et al., 2017) were used at either 5 doses (35, 3.5, 0.35, 0.035 and 0.0035 μ M) or 10 445 doses (16, 5.6, 1.8, 0.6, 0.21, 0.07, 0.02, 0.008, 0.002 and 0.0008 μ M) as indicated. The 446 compounds were transferred in replicate from compound source plates to the cell plates using the 447 HighRes Pin Tool. DMSO was used as a negative control and JQ1 (250 nM) (a bromodomain 448 inhibitor) as positive control, based on earlier studies showing potent reduction of total MUC1 449 mRNA levels (data not shown). After 48 h incubation, cells were fixed 20 min in 4% PFA 450 (Electron Microscopy Sciences) in PBS, washed twice, then permeabilized (10 min) with 0.5% 451 Triton X-100 (Sigma-Aldrich) in PBS and washed once more. Cells were blocked for 10 min at 452 RT with Blocking solution (100mM Tris HCL pH8; 150mM NaCL; 5g/L Blocking Reagent 453 [Roche]), then incubated 90 min at RT with 1:2000, monoclonal mouse anti-MUC1 (214D4) 454 antibody (Millipore) in Roche Blocking solution, followed by four PBS wash cycles. Then the 455 secondary antibody Alexa Fluor® 546 Goat anti-mouse IgG, Thermo Fisher Scientific and 456 Hoechst 33342 stain, Thermo Fisher Scientific, were applied at a 1:1000 dilution in Roche 457 blocking solution and incubated at RT for 45 min, followed by four PBS wash cycles. Plates 458 were then sealed with a Plate Loc plate and stored in a Liconic incubator at 10°C until imaging.

459

460 Image acquisition and analysis was as described in the Fluorescence image acquisition and 461 analysis section. Upon image analysis, two parameters were selected, i) total MUC1 cytoplasmic

intensity and ii) cell number as was detected by Hoechst 33342 stained nuclei. MUC1 levels in 462

463 the presence of DMSO or of JQ1 were defined, respectively as 0 and -100% activity. Values for

464 test compounds were normalized accordingly. Cell number was normalized to DMSO control.

465 All compound concentrations showing > -20% reduction in cell number were masked out. Based

466 on \pm 3 median absolute deviation value, hit calling criteria for the initial 5 doses screen were

467 chosen as MUC1 reduction > 30% in 2 or more consecutive concentrations for both replicates. 468 For the initial 10 doses screen, dose response curves were generated for each parameter using

469 Genedata Screener (Genedata AG), and positive hits for the profiling screens were selected based

470 on the compound's activity in reducing MUC1 abundance without cell toxicity.

471 For the RT-PCR-based screen (Bittker, 2012), P cells seeded at 2000 cells/well in 384-well, clear 472

bottom, white wall plates were grown for 24 h, then treated with profiling compounds transferred

473 by pinning to duplicate plates. JQ1 (250 nM) and DMSO were used for controls as above. After

474 24 h, cells were washed and cDNAs generated using ABI Cells-to-Ct kit (Thermo Fisher

475 Scientific, Waltham, MA). MUC1 and HMBS delta Cp values were determined using a Roche

476 LightCycler 480 Instrument in 5µL reactions using TaqMan probes for MUC1 FAM (4351368

477 assay ID Hs00159357_m1) and HMBS VIC (4448486- assay ID Hs00609297_m1) (Thermo

478 Fisher Scientific). The fold change effect of the compounds on total MUC1 mRNA was

479 normalized to JQ1 and DMSO controls, as described above.

480

481 For the viability profiling screen, P cells were seeded 12 h prior to profiling compound treatment

- 482 at a density of 12,000 cells/well in 384 well Cell Carrier Ultra plates (Perkin Elmer), pre-coated
- 483 with 0.25 mg/mL Synthemax II SC Substrate (Corning). After 24 h, CellEvent Caspase-3/7
- 484 Green Detection Reagent (Thermo Fisher Scientific) and DRAQ7 (Biostatus) were added at

- 485 1:5000 final dilution. Cells were imaged daily during 7 days to monitor viability. Image
- 486 acquisition was done as described below and viability was assessed as number of live cells at the
- 487 day 6, when most of DMSO treated wells reached about 95% of confluence.
- 488

489 Mice

490

Adult, 7-week-old male C57BL/6J mice were purchased from Jackson Laboratory (Bar Harbor,
ME) and maintained in specific pathogen-free conditions at the Beth Israel Deaconess Medical
Center (BIDMC) and allowed to acclimate for 1 week before use in experiments. All mice used
in this study were 8–12 weeks old.

495

496 Administration of SYK inhibitor R788497

498 SYK inhibitor R788 was provided by Rigel Pharmaceuticals (South San Francisco, CA). Mice 499 chow was prepared by Research Diets (New Brunswick, NJ). C57BL/6J mice were fed chow 500 containing 3 g/kg R788 ad libitium for 10 days before experimentation. Control mice were fed 501 normal chow.

502

503 Mesenteric Ischemia-Reperfusion (I/R)

504

505 All animal procedures were performed in accordance with the guidelines and approval of the 506 Institutional Animal Care and Use Committee (IACUC) of the BIDMC. Mice were randomly 507 assigned to sham or I/R groups and were anesthetized by intraperitoneal injection of 72 mg/kg 508 pentobarbital. Animals were subjected to I/R, as previously described (Pamuk et al., 2010). Mice 509 were anesthetized with 72 mg/kg nembutal (Butler Schein Animal Health) given i.p. 510 Additionally, 36 mg/kg nembuttal was given s.c. during the experiment as needed to maintain 511 anesthesia. All procedures were performed on anesthetized, spontaneously breathing animals 512 with body temperature maintained at 37°C with a controlled heating pad. A midline laparotomy 513 was performed, and the superior mesenteric artery was identified and isolated. Ischemia was 514 induced by application of ~ 85 g of pressure fir 30 min via a small nontraumatic vascular clamp 515 (Roboz Surgical Instruments, Gaithersburg, MD). After 30 min of ischemia, the clamp was 516 removed, the laparotomy incision was repaired with 4-0 Sofsilk (Covidien, Mansfield, MA), the 517 mice were resuscitated with 1.0 ml of prewarmed sterile PBS s.c., and the intestine was allowed 518 to reperfuse for 180 min. Sham-operated mice were subjected to the same operative procedure as 519 the experimental group except that clamping of the superior mesenteric artery was not 520 performed. At the conclusion of the reperfusion period, mice were euthanized by carbon dioxide 521 asphysiation, following the IACUC Guidelines of the BIDMC. Lung removal consisted of intact 522 extraction of the bronchial tree after expansion with tracheal administration of 200-300 of ice-523 cold 10% phosphate-buffered formalin and fixed overnight in 10% phosphate- buffered formalin at 4°C. Formalin-fixed lung tissues were washed extensively in PBS, processed, and embedded 524 525 in paraffin for immunohistochemical analysis.

- 526
- 527 Immunohistochemistry
- 528

529 Immunohistochemical staining was performed on formalin-fixed paraffin sections of lung 530 tissues. The samples were subjected to rehydration and antigen retrieval by overnight immersion 531 in 10mM citric acid buffer (pH 6), for overnight at 60° C. Following antigen retrieval, 532 endogenous peroxidase was blocked with 0.3% H2O2 for 15 min followed by blocking with 533 2.5% fetal bovine serum (FBS) in PBS for 30 min. Sections were then incubated at 4 C overnight 534 with primary antibodies in 2.5% BSA in PBS ((1:500, monoclonal Armenian hamster anti-535 MUC1, Abcam; 1:400, Rhodamine Phalloidin, Cytoskeleton Inc). Following washing, the 536 sections were incubated for 1 h at 37° C with secondary antibody diluted in 2.5% BSA in PBS 537 (1:500, Alexa Fluor® 488-conjugated AffiniPure Goat anti-Armenian hamster IgG, Jackson 538 Immunoresearch; 1:500). Slides were washed and mounted in ProLong Gold Antifade Mountant 539 with DAPI (Thermo Fischer Scientific).

- 540
- 541

542 Statistical analysis

543 Statistical analysis was performed and presented using Graphpad Prism version 7.0 software. All

544 data are presented as means \pm standard deviation for 'n' experiments unless otherwise specified

545 in the figure legends. The exact value of 'n' for each experiment can be found in the figure

legends. Statistical comparisons of two groups for a single variable with normal distributionswere analyzed by unpaired t test. Statistical comparisons of two or more groups with one

were analyzed by unpaired t test. Statistical comparisons of two or more groups with one
 independent variable were analyzed by One-way ANOVA with Tukey post-tests. Statistical

548 independent variable were analyzed by One-way ANOVA with Tukey post-tests. Statistical 549 comparisons of two or more groups with two independent variables were analyzed by Two-way

- 550 ANOVA with Tukey post-tests. *p < 0.05 **p < 0.01 ***p < 0.001 ****p < 0.001
- 551
- 552
- 553

554 **References**

555

556 Argade, A., Bhamidipati, S., Li, H., Sylvain, C., Clough, J., Carroll, D., Keim, H., Braselmann,


- 557 S., Taylor, V., Zhao, H., et al. (2015). Design, synthesis of diaminopyrimidine inhibitors
- targeting IgE- and IgG-mediated activation of Fc receptor signaling. Bioorg Med Chem Lett 25,
 2122-2128.
- 560 Ashburn, T.T., and Thor, K.B. (2004). Drug repositioning: identifying and developing new uses
- 561 for existing drugs. Nature Reviews Drug Discovery 3, 673-683.
- 562 Bittker, J.A. (2012). High-Throughput RT-PCR for small-molecule screening assays. Curr
- 563 Protoc Chem Biol *4*, 49-63.
- 564 Bussel, J., Arnold, D.M., Grossbard, E., Mayer, J., Trelinski, J., Homenda, W., Hellmann, A.,
- 565 Windyga, J., Sivcheva, L., Khalafallah, A.A., *et al.* (2018). Fostamatinib for the treatment of
- adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized,placebo-controlled trials. Am J Hematol *93*, 921-930.
- 568 Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et
- al. (2020). A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl
 J Med.
- 571 Castro, M., King, T.S., Kunselman, S.J., Cabana, M.D., Denlinger, L., Holguin, F., Kazani, S.D.,
- 572 Moore, W.C., Moy, J., Sorkness, C.A., *et al.* (2014). Effect of vitamin D3 on asthma treatment

- 573 failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized
- 574 clinical trial. JAMA *311*, 2083-2091.
- 575 Corsello, S.M., Bittker, J.A., Liu, Z., Gould, J., McCarren, P., Hirschman, J.E., Johnston, S.E.,
- 576 Vrcic, A., Wong, B., Khan, M., *et al.* (2017). The Drug Repurposing Hub: a next-generation 577 drug library and information resource. Nat Med *23*, 405-408.
- 578 d'Alessandro, M., Bergantini, L., Cameli, P., Lanzarone, N., Antonietta Mazzei, M., Alonzi, V.,
- 579 Sestini, P., and Bargagli, E. (2020). Serum KL-6 levels in pulmonary Langerhans' cell
- 580 histiocytosis. Eur J Clin Invest, e13242.
- 581 Dong, E., Du, H., and Gardner, L. (2020). An interactive web-based dashboard to track COVID-
- 582 19 in real time. Lancet Infect Dis.
- 583 Dvela-Levitt, M., Kost-Alimova, M., Emani, M., Kohnert, E., Thompson, R., Sidhom, E.H.,
- 584 Rivadeneira, A., Sahakian, N., Roignot, J., Papagregoriou, G., et al. (2019). Small Molecule
- Targets TMED9 and Promotes Lysosomal Degradation to Reverse Proteinopathy. Cell *178*, 521-535 e523.
- 587 Geahlen, R.L. (2014). Getting Syk: spleen tyrosine kinase as a therapeutic target. Trends
- 588 Pharmacol Sci 35, 414-422.
- 589 Grein, J. (2020). Compassionate Use of Remdesivir for Patients with Severe Covid-19. New
- 590 England Journal of Medicine.
- 591 Hilgendorf, I., Eisele, S., Remer, I., Schmitz, J., Zeschky, K., Colberg, C., Stachon, P., Wolf, D.,
- 592 Willecke, F., Buchner, M., *et al.* (2011). The oral spleen tyrosine kinase inhibitor fostamatinib
- 593 attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice.
- 594 Arterioscler Thromb Vasc Biol *31*, 1991-1999.
- 595 Ishizaka, A., Matsuda, T., Albertine, K.H., Koh, H., Tasaka, S., Hasegawa, N., Kohno, N.,
- 596 Kotani, T., Morisaki, H., Takeda, J., *et al.* (2004). Elevation of KL-6, a lung epithelial cell
- 597 marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome. Am J Physiol
- 598 Lung Cell Mol Physiol 286, L1088-1094.
- 599 Kato, K., Chang, E.H., Chen, Y., Lu, W., Kim, M.M., Niihori, M., Hecker, L., and Kim, K.C.
- 600 (2020). MUC1 contributes to goblet cell metaplasia and MUC5AC expression in response to 601 cigarette smoke in vivo. Am J Physiol Lung Cell Mol Physiol.
- Kato, K., Lillehoj, E.P., Lu, W., and Kim, K.C. (2017). MUC1: The First Respiratory Mucin
 with an Anti-Inflammatory Function. J Clin Med 6.
- Kunwar, S., Devkota, A.R., and Ghimire, D.K. (2016). Fostamatinib, an oral spleen tyrosine
- 605 kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized
- 606 controlled trials. Rheumatol Int *36*, 1077-1087.
- Li, Y.Y., Hsieh, L.L., Tang, R.P., Liao, S.K., and Yeh, K.Y. (2009). Macrophage-derived
- 608 interleukin-6 up-regulates MUC1, but down-regulates MUC2 expression in the human colon
- 609 cancer HT-29 cell line. Cell Immunol 256, 19-26.
- 610 McAdoo, S.P., Prendecki, M., Tanna, A., Bhatt, T., Bhangal, G., McDaid, J., Masuda, E.S.,
- 611 Cook, H.T., Tam, F.W.K., and Pusey, C.D. (2020). Spleen tyrosine kinase inhibition is an
- 612 effective treatment for established vasculitis in a pre-clinical model. Kidney Int.
- 613 McAdoo, S.P., Reynolds, J., Bhangal, G., Smith, J., McDaid, J.P., Tanna, A., Jackson, W.D.,
- Masuda, E.S., Cook, H.T., Pusey, C.D., et al. (2014). Spleen tyrosine kinase inhibition attenuates
- autoantibody production and reverses experimental autoimmune GN. J Am Soc Nephrol 25,
- 616 2291-2302.
- 617 McAdoo, S.P., and Tam, F.W. (2011). Fostamatinib Disodium. Drugs Future *36*, 273.

- 618 Mendes, A.I., Matos, P., Moniz, S., Luz, S., Amaral, M.D., Farinha, C.M., and Jordan, P. (2011).
- 619 Antagonistic regulation of cystic fibrosis transmembrane conductance regulator cell surface
- 620 expression by protein kinases WNK4 and spleen tyrosine kinase. Mol Cell Biol *31*, 4076-4086.
- Mocsai, A., Ruland, J., and Tybulewicz, V.L. (2010). The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol *10*, 387-402.
- Moore, J.B., and June, C.H. (2020). Cytokine release syndrome in severe COVID-19. Science
- 624 368, 473-474.
- 625 Muus, C. (2020). Integrated analyses of single-cell atlases reveal age, gender, and smoking status
- 626 associations with cell type-specific expression of mediators of SARS-CoV-2 viral entry and
- 627 highlights inflammatory programs in putative target cells. BioRxiv.
- 628 Na, H.G., Bae, C.H., Choi, Y.S., Song, S.Y., and Kim, Y.D. (2016). Spleen tyrosine kinase
- 629 induces MUC5AC expression in human airway epithelial cell. Am J Rhinol Allergy *30*, 89-93.
- 630 Nakashima, T., Yokoyama, A., Ohnishi, H., Hamada, H., Ishikawa, N., Haruta, Y., Hattori, N.,
- Tanigawa, K., and Kohno, N. (2008). Circulating KL-6/MUC1 as an independent predictor for
- 632 disseminated intravascular coagulation in acute respiratory distress syndrome. J Intern Med 263,
- 633 432-439.
- 634 Newland, A., Lee, E.J., McDonald, V., and Bussel, J.B. (2018). Fostamatinib for
- 635 persistent/chronic adult immune thrombocytopenia. Immunotherapy 10, 9-25.
- 636 Ohtsuki, Y., Fujita, J., Hachisuka, Y., Uomoto, M., Okada, Y., Yoshinouchi, T., Lee, G.H.,
- 637 Furihata, M., and Kohno, N. (2007). Immunohistochemical and immunoelectron microscopic
- 638 studies of the localization of KL-6 and epithelial membrane antigen (EMA) in presumably
- normal pulmonary tissue and in interstitial pneumonia. Med Mol Morphol 40, 198-202.
- 640 Pamuk, O.N., Lapchak, P.H., Rani, P., Pine, P., Dalle Lucca, J.J., and Tsokos, G.C. (2010).
- 641 Spleen tyrosine kinase inhibition prevents tissue damage after ischemia-reperfusion. Am J
- 642 Physiol Gastrointest Liver Physiol 299, G391-399.
- 643 Pushpakom, S., Iorio, F., Eyers, P.A., Escott, K.J., Hopper, S., Wells, A., Doig, A., Guilliams,
- T., Latimer, J., McNamee, C., *et al.* (2019). Drug repurposing: progress, challenges and
- 645 recommendations. Nat Rev Drug Discov 18, 41-58.
- Ruan, Q., Yang, K., Wang, W., Jiang, L., and Song, J. (2020). Clinical predictors of mortality
- due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. IntensiveCare Med.
- 649 Sakai, M., Kubota, T., Ohnishi, H., and Yokoyama, A. (2013). A novel lung injury animal model
- using KL-6-measurable human MUC1-expressing mice. Biochem Biophys Res Commun 432,
 460-465.
- 652 Singh, R., Masuda, E.S., and Payan, D.G. (2012). Discovery and Development of Spleen
- Tyrosine Kinase (SYK) Inhibitors. Journal of Medicinal Chemistry 55, 3614-3643.
- 654 Smith, J., McDaid, J.P., Bhangal, G., Chawanasuntorapoj, R., Masuda, E.S., Cook, H.T., Pusey,
- 655 C.D., and Tam, F.W. (2010). A spleen tyrosine kinase inhibitor reduces the severity of
- established glomerulonephritis. J Am Soc Nephrol 21, 231-236.
- 657 Uhlen, M., Fagerberg, L., Hallstrom, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A.,
- 658 Sivertsson, A., Kampf, C., Sjostedt, E., Asplund, A., et al. (2015). Proteomics. Tissue-based map
- of the human proteome. Science *347*, 1260419.
- 660 Vestbo, J. (2002). Epidemiological studies in mucus hypersecretion. Novartis Found Symp 248,
- 661 3-12; discussion 12-19, 277-282.

- 662 Weinblatt, M.E., Kavanaugh, A., Genovese, M.C., Musser, T.K., Grossbard, E.B., and Magilavy,
- D.B. (2010). An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis. New
 England Journal of Medicine *363*, 1303-1312.
- 665 Wilson, J.G. (2020). Cytokine profile in plasma of severe COVID-19 does not differ from ARDS 666 and sepsis. medRxiv.
- 667 Yi, Y.S., Son, Y.J., Ryou, C., Sung, G.H., Kim, J.H., and Cho, J.Y. (2014). Functional roles of
- 668 Syk in macrophage-mediated inflammatory responses. Mediators Inflamm 2014, 270302.
- 669 Zhang, C., Wu, Z., Li, J.W., Zhao, H., and Wang, G.Q. (2020). The cytokine release syndrome
- 670 (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be
- 671 the key to reduce the mortality. Int J Antimicrob Agents, 105954.
- 672 Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al.
- 673 (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in
- Wuhan, China: a retrospective cohort study. Lancet *395*, 1054-1062.
- 675
- 676
- 677
- 678





Α







Image credit: Human Protein Atlas












Ε







В





MUC1
 Hoechst





measurement





Vehicle Fostamatinib

Α